- Home
- NDRA vs CPHI Comparison
NDRA vs CPHI Comparison
Compare NDRA & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDRA
- CPHI
- Stock Information
- Founded
- NDRA 2007
- CPHI N/A
- Country
- NDRA United States
- CPHI China
- Employees
- NDRA N/A
- CPHI N/A
- Industry
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CPHI Biotechnology: Pharmaceutical Preparations
- Sector
- NDRA Health Care
- CPHI Health Care
- Exchange
- NDRA Nasdaq
- CPHI Nasdaq
- Market Cap
- NDRA 3.9M
- CPHI 4.7M
- IPO Year
- NDRA 2017
- CPHI N/A
- Fundamental
- Price
- NDRA $6.22
- CPHI $1.93
- Analyst Decision
- NDRA Strong Buy
- CPHI
- Analyst Count
- NDRA 1
- CPHI 0
- Target Price
- NDRA $38.00
- CPHI N/A
- AVG Volume (30 Days)
- NDRA 39.3K
- CPHI 26.1K
- Earning Date
- NDRA 11-14-2025
- CPHI 11-12-2025
- Dividend Yield
- NDRA N/A
- CPHI N/A
- EPS Growth
- NDRA N/A
- CPHI N/A
- EPS
- NDRA N/A
- CPHI N/A
- Revenue
- NDRA N/A
- CPHI $4,396,201.00
- Revenue This Year
- NDRA N/A
- CPHI N/A
- Revenue Next Year
- NDRA N/A
- CPHI N/A
- P/E Ratio
- NDRA N/A
- CPHI N/A
- Revenue Growth
- NDRA N/A
- CPHI N/A
- 52 Week Low
- NDRA $2.90
- CPHI $1.20
- 52 Week High
- NDRA $22.68
- CPHI $3.35
- Technical
- Relative Strength Index (RSI)
- NDRA 68.71
- CPHI 60.72
- Support Level
- NDRA $5.30
- CPHI $1.85
- Resistance Level
- NDRA $6.45
- CPHI $1.97
- Average True Range (ATR)
- NDRA 0.40
- CPHI 0.11
- MACD
- NDRA 0.12
- CPHI -0.01
- Stochastic Oscillator
- NDRA 73.45
- CPHI 78.00
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.